Cipla launches respiratory inhalation therapy product Niveoli in India

Published On 2019-04-12 06:11 GMT   |   Update On 2021-08-16 08:37 GMT

New Delhi: Drug major Cipla Friday announced the launch of its proprietary respiratory inhalation therapy product 'Niveoli' in India. Niveoli is used in respiratory inhalation therapy that addresses an unmet need associated with obstructive airway diseases (OAD) such as asthma and chronic obstructive pulmonary disorder (COPD), Cipla said in a BSE filing.


Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow.The main symptoms include shortness of breath and cough with sputum production


Also Read: Cipla to launch Cinacalcet Hydrochloride tablets, a generic version of Sensipar


The company said Niveoli, extra-fine particle beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults, targets drug delivery to the small airways.


"We see our market leadership, as well as the range and depth of our R&D and manufacturing capabilities in this therapy as a privilege and a responsibility to do more for patients," Cipla Head - India business Nikhil Chopra said.




Cipla Limited is a multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The company primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.






Tags:    
Article Source : With input

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News